Pricing Log in Create free account
Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−51.5%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.13 0.44 −0.65%
Market cap
$39.0B
P/E
44.8×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Royalty Pharma PLC (RPRX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 26 added · 23 removed · 61 modified
P2I1A: 4 modified
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 39 added · 16 removed · 62 modified
P2I1A: 1 modified
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 4, 2026 5.07 Submission of matters to a vote of security holders
8-K May 22, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 13, 2026 7.01 Regulation FD disclosure
10-K Dec 31, 2025 1: 18 added · 23 removed · 33 modified
1A: 12 added · 40 removed · 78 modified
7: 81 added · 73 removed · 61 modified
8-K Feb 11, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 20, 2025 5.02 Departure or appointment of directors or officers Officer departure
8-K Dec 19, 2025 7.01 Regulation FD disclosure
10-Q Sep 30, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 16, 2025 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 8, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 10, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 9, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 15, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 8, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.